Exicure, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $7.8M
- Price
- $1.19
- % Change (Daily % change from the live per-ticker quote feed.)
- -8.46%
- Volume
- 152.0K
About
Exicure, Inc. is a biotechnology firm that utilizes its unique spherical nucleic acid (SNA) platform to create therapies for neurological conditions and hair loss. Its primary experimental candidate, SCN9A, is currently undergoing preclinical evaluation for addressing neuropathic and chronic pain. The company has entered into a strategic partnership with AbbVie Inc. to advance SNA-based solutions for various hair loss conditions, under a collaboration, option, and license agreement. Additionally, a separate collaborative effort with Ipsen S.A. aims to investigate, develop, and commercialize novel spherical nucleic acids targeting Huntington's disease and Angelman syndrome. Established in 2011, Exicure's corporate base is located in Chicago, Illinois.
Quick stats
Shares outstanding6.5M
Computed float2.7M
Float / shares41.0%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001698530
Websitehttps://www.exicuretx.com
AI Summary
AI-generated1/8
minorbullishoffering
Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance
Exicure announced it will issue 172,058 shares of common stock to GPCR Therapeutics to settle a $1.0 million clinical milestone payment obligation.
The payment was triggered by the completion of the Phase 2 clinical trial of Burixafor (GPC-100) and the submission of the Clinical Study Report to the FDA.
The shares will be issued at a deemed value of $5.81 per share, a move the CEO says will preserve cash and maintain financial flexibility.
Red flags
- Company description notes suspension of clinical and development activities
- Company is exploring strategic alternatives